These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32140806)

  • 1. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.
    Huber D; Seitz S; Kast K; Emons G; Ortmann O
    Arch Gynecol Obstet; 2020 Apr; 301(4):875-884. PubMed ID: 32140806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
    Moorman PG; Havrilesky LJ; Gierisch JM; Coeytaux RR; Lowery WJ; Peragallo Urrutia R; Dinan M; McBroom AJ; Hasselblad V; Sanders GD; Myers ER
    J Clin Oncol; 2013 Nov; 31(33):4188-98. PubMed ID: 24145348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
    van Bommel MHD; IntHout J; Veldmate G; Kets CM; de Hullu JA; van Altena AM; Harmsen MG
    Hum Reprod Update; 2023 Mar; 29(2):197-217. PubMed ID: 36383189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
    Cibula D; Zikan M; Dusek L; Majek O
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1197-207. PubMed ID: 21916573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.
    Park J; Huang D; Chang YJ; Lim MC; Myung SK
    Carcinogenesis; 2022 Apr; 43(3):231-242. PubMed ID: 34958358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.
    Huber D; Seitz S; Kast K; Emons G; Ortmann O
    Arch Gynecol Obstet; 2020 Sep; 302(3):715-720. PubMed ID: 32719921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
    Huber D; Seitz S; Kast K; Emons G; Ortmann O
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2035-2045. PubMed ID: 33885953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
    Jernström H; Sandberg T; Bågeman E; Borg A; Olsson H
    Int J Gynecol Cancer; 2006; 16 Suppl 2():497. PubMed ID: 17010055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer of the breast and reproductive tract in relation to use of oral contraceptives.
    Schlesselman JJ
    Contraception; 1989 Jul; 40(1):1-38. PubMed ID: 2673658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing.
    Jernström H; Loman N; Johannsson OT; Borg A; Olsson H
    Eur J Cancer; 2005 Oct; 41(15):2312-20. PubMed ID: 16118051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptives and gynecologic cancer: an update for the 1990s.
    Kaunitz AM
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1171-6. PubMed ID: 1415442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Xia YY; Gronwald J; Karlan B; Lubinski J; McCuaig JM; Brooks J; Moller P; Eisen A; Sun S; Senter L; Bordeleau L; Neuhausen SL; Singer CF; Tung N; Foulkes WD; Sun P; Narod SA; Kotsopoulos J;
    Gynecol Oncol; 2022 Mar; 164(3):514-521. PubMed ID: 35063280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
    Figueiredo JC; Haile RW; Bernstein L; Malone KE; Largent J; Langholz B; Lynch CF; Bertelsen L; Capanu M; Concannon P; Borg A; Børresen-Dale AL; Diep A; Teraoka S; Torngren T; Xue S; Bernstein JL
    Breast Cancer Res Treat; 2010 Feb; 120(1):175-83. PubMed ID: 19597986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Narod SA; Dubé MP; Klijn J; Lubinski J; Lynch HT; Ghadirian P; Provencher D; Heimdal K; Moller P; Robson M; Offit K; Isaacs C; Weber B; Friedman E; Gershoni-Baruch R; Rennert G; Pasini B; Wagner T; Daly M; Garber JE; Neuhausen SL; Ainsworth P; Olsson H; Evans G; Osborne M; Couch F; Foulkes WD; Warner E; Kim-Sing C; Olopade O; Tung N; Saal HM; Weitzel J; Merajver S; Gauthier-Villars M; Jernstrom H; Sun P; Brunet JS
    J Natl Cancer Inst; 2002 Dec; 94(23):1773-9. PubMed ID: 12464649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
    Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
    Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal contraception and risk of cancer.
    Cibula D; Gompel A; Mueck AO; La Vecchia C; Hannaford PC; Skouby SO; Zikan M; Dusek L
    Hum Reprod Update; 2010; 16(6):631-50. PubMed ID: 20543200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Contraceptive Use and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Systematic Review and Meta-Analysis of Case-Control Studies.
    Barańska A; Kanadys W
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
    Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
    Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.